Physician profile
Chikako Ono
NPI 1699903526
$4,259.55
in general payments reported to CMS, 2019-2025
21 companies · $15.23 in 2025
The $15.23 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $95.36 · 2021: $433 · 2022: $311 · 2023: $2,230 · 2024: $983 · 2025: $15.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,943 · Travel and Lodging: $1,119 · Education: $99.00 · Consulting Fee: $66.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,943.18 |
| Travel and Lodging | $1,119.16 |
| Education | $99.00 |
| Consulting Fee | $66.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $1,714.72 | 2023 | Ffrct |
| Boehringer Ingelheim Pharmaceuticals, INC. | $431.42 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $362.39 | 2023-2024 | Opsumit, Uptravi |
| United Therapeutics Corporation | $296.60 | 2019-2024 | Tyvaso, Orenitram, Remodulin |
| Inari Medical, INC. | $217.15 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pfizer INC. | $128.17 | 2019 | |
| Medtronic, INC. | $114.50 | 2023 | Corevalve Evolut R |
| Daxor Corporation | $109.89 | 2024 | Bva-100 |
| Edwards Lifesciences Corporation | $106.09 | 2021 | |
| Penumbra, INC. | $104.03 | 2024 | Indigo System |
| Amgen INC. | $100.45 | 2024 | Repatha |
| Medtronic Vascular, INC. | $95.36 | 2020 | |
| Abbott Laboratories | $93.13 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $92.76 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.64 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $65.66 | 2024 | Winrevair |
| E.R. Squibb & Sons, L.L.C. | $65.21 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.19 | 2024 | Lifevest |
| Livanova USA, INC. | $25.29 | 2023 | Lifesparc |
| Janssen Pharmaceuticals, INC | $20.67 | 2021 | |
| Abiomed | $15.23 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chikako Ono listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.